Navigation Links
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Date:2/4/2008

HORSHAM, Pa., Feb. 4 /PRNewswire/ -- Centocor, Inc. announced today that the Biologics License Application (BLA) for ustekinumab (CNTO 1275) has been accepted for review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic moderate to severe plaque psoriasis. Ustekinumab is a new, human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), naturally occurring proteins that are important in regulating immune responses and that are thought to be associated with some immune-mediated inflammatory disorders, including psoriasis.

"We are pleased by the FDA's acceptance of our Biologics License Application for review of ustekinumab," stated Jerome A. Boscia, M.D., senior vice president, Clinical R&D, Centocor, Inc. "Ustekinumab has yielded promising efficacy and safety results in Phase 3 clinical trials, and we look forward to working closely with the FDA during their ongoing review of this potential new treatment for psoriasis."

Centocor, Inc. announced that it had submitted the BLA for ustekinumab in December 2007 based on its comprehensive development program including data from two large Phase 3 multicenter, randomized, double-blind, placebo- controlled trials involving nearly 2,000 patients that evaluated the safety and efficacy of ustekinumab in the treatment of moderate to severe plaque-type psoriasis. The primary endpoint of both studies was the proportion of patients who achieved at least a 75 percent reduction in psoriasis as measured by the Psoriasis Area and Severity Index (PASI 75). Acceptance of the BLA filing does not mean that a license has been issued for this product nor does it represent any evaluation of the adequacy of the data submitted in the BLA. In December 2007 the Marketing Authorization Application (MAA) for ustekinumab was submitted in Europe and is currently under review by the European Medicines Agency (
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... Erlanger, Kentucky (PRWEB) October 30, 2014 Avure ... of the 525L, the newest member of its fleet of ... to be reaching an anniversary as we return to PackExpo ... a year ago in Las Vegas,” said Jeff Williams, CEO ... extremely well, and we’re pleased to be meeting the challenges ...
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... hold a conference call and live audio webcast on ... discuss its third quarter 2014 financial results. ... by dialing (888) 347-1165 for domestic callers or (412) ... webcast live under the investor relations section of the ...
(Date:10/27/2014)... 2014 The new research report, ... & Medium), Sub-type (Primary & Secondary), and End-User ... Transportation & Power Generation) - Trends and Forecasts ... with analysis and forecasting of the market size. ... with 52 Figures spread through 146 Pages and ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... Strategic Marketing ... Expertise, ... today announced that it has appointed David P.,Pauluzzi to its Board ... Partners, a Chicago-based private equity firm,specializing in the healthcare sector., ...
... DRRX ) announced today financial results for the ... were $6.6 million for the,three months ended December 31, ... 2006. Net loss for the three months ended December ... of $9.8 million for the same period in,2006., ...
... 5 Physicians Reference,Laboratory ("PRL") announced today that it ... date. Under the marketed,name COMPLeTe Care HPV, the test ... risk types of HPV which can lead to,cervical cancer., ... form of female,cancer with an incidence of over 500,000 ...
Cached Biology Technology:Transgenomic Appoints David Pauluzzi to Board of Directors 2Transgenomic Appoints David Pauluzzi to Board of Directors 3DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 2DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 3DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 4DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 5DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 6DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 7DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 8DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 9Physicians Reference Laboratory Announces New Diagnostic for Women's Health 2
(Date:10/31/2014)... and his team have been studying the behavior ... Austrian Alps for years. They observed that ravens ... grooming and playing. However, they also observed that ... third individual. Although in about 50 % of ... up the two affiliating ravens, intervening can be ...
(Date:10/30/2014)... German . ... humans to behave socially? This is one of the ... Previous studies assumed that it is almost impossible to ... Max Planck Institute for Evolutionary Biology have now demonstrated ... the cooperative behaviour of others. However, the possibilities available ...
(Date:10/30/2014)... , Oct. 29, 2014  Securus ... criminal justice technology solutions for public safety, ... it has deployed exciting enhancements to its ... analytics to provide actionable intelligence and focused ... continues to drive technological innovation through identifying ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2
... Could our mother,s diet at the time we are conceived ... is at the heart of a new study based on ... We inherit our DNA the genetic blueprint that ... DNA from our mothers and 50% from our fathers. Apart ...
... responsible for some of the worst air quality conditions worldwide ... changes in land use and population density, according to a ... Field of the University of Toronto. "During the late ... fire-prone during drought years, marking the period when one of ...
... BEVERLY, Mass., Feb. 17 LocatePLUS Holdings ... business-to-government provider of investigative, identity validation, and ... 26, 2009 election of an entirely independent ... independent Board through the consent of a ...
Cached Biology News:'Experiment of nature' examines how mother's diet may impact on child's health 2'Experiment of nature' examines how mother's diet may impact on child's health 3Atmospheric scientists trace the human role in Indonesian forest fires 2LocatePLUS Announces Election of Independent Board 2LocatePLUS Announces Election of Independent Board 3LocatePLUS Announces Election of Independent Board 4
... Application: Pyronin Y is most ... green to selectively and differentially stain ... In a dichromatic dye solution, Pyronin ... green stains DNA green. ...
... cassette is designed to allow ... The prokaryotic promoter gb2 driving the ... slightly modified version of the Em7 ... than the generally used Tn5 promoter. ...
... AMPure is a magnetic bead-based ... no sample transfer, centrifugation or ... small and large PCR extension ... microplates. Agencourt AMPure can easily ...
... a magnetic bead-based PCR purification ... transfer, centrifugation or filtration steps. ... large PCR extension products in ... AMPure can easily be performed ...
Biology Products: